Champions of Cell and Gene Therapy – The Medicine Maker
How do we ensure that not only the rich benefit from cell and gene therapy? Rob Collison of Cambridge Consultants says: It’s about more than cutting costs
How do we ensure that not only the rich benefit from cell and gene therapy? Rob Collison of Cambridge Consultants says: It’s about more than cutting costs
This whitepaper describes the benefits of introducing advanced wireless capabilities into surgical and critical care settings, the technical approaches to achieve this, and the challenges that can arise. It concludes with our vision for some exemplar use cases.
The future promises a digitally connected healthcare system that empowers both patients and carers alike. So, what’s the next step for pharma companies and device developers with ambitions in the space?
The current state of in vitro diagnostics is no longer fit for purpose. Inadequate procedures mean that critical insights are often missed, while expenditure statistics on both sides of the Atlantic reveal lagging levels of investment.
We’re ramping up our commitment to The Engine, the ambitious venture ecosystem spun out of MIT to support ‘Tough Tech’ companies and solve key challenges in climate change, human health and advanced systems.